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Background and Aims The potential for transmission of pathogenic organisms is a problem 
inherent to the current reusable duodenoscope design. Recent outbreaks of multidrug resistant 
pathogenic organisms transmitted via duodenoscopes has brought to light the urgency of this 
problem. Microbiological culturing of duodenoscopes and reprocessing with repeat high-level 
disinfection or liquid chemical sterilization have been offered as supplemental measures to 
enhance duodenoscope reprocessing by the U.S. Food and Drug Administration (FDA). This 
study aims to compare the efficacy of reprocessing duodenoscopes with double high-level 
disinfection (DHLD) versus liquid chemical sterilization (LCS).   
 
Methods We prospectively evaluated 2 different modalities of duodenoscope reprocessing from 
October 23, 2017 to September 24, 2018.  Eligible duodenoscopes were randomly segregated 
to be reprocessed by either DHLD or LCS. Duodenoscopes were randomly cultured after 
reprocessing for surveillance based on an internal protocol.  
 
Results During the study time period, there were 878 postreprocessing surveillance cultures 
(453 in the DHLD group and 425 in the LCS group).  Of all of the cultures, 17 were positive for 
any organism (1.9%).  There was no significant difference of positive cultures when comparing 
the duodenoscopes undergoing DHLD (8 positive cultures, 1.8%) to duodenoscopes undergoing 
LCS (9 positive cultures, 2.1%, p=0.8). Both groups had 2 cultures that grew high-concern 
organisms (0.5% vs. 0.5%, p=1.0). No multi-drug resistant organisms (MDRO), including 
carbapenem-resistant enterobacteriaceae (CRE), were detected.  
 
Conclusions DHLD and LCS both resulted in a low rate of positive cultures, both for all 
organisms and for high-concern organisms, but neither process completely eliminated positive 











Background and Aims 
ERCP is an invasive endoscopic procedure that provides important, often lifesaving therapy for 
diseases of the pancreas and biliary tracts. The potential for transmission of pathogenic 
organisms due to incomplete reprocessing is a problem inherent to current reusable 
duodenoscope design. Recent reports of multidrug resistant pathogenic organisms transmitted 
via duodenoscopes has brought to light the severity of this problem.1-3 Since the first cases of 
potential transmission of drug resistant organisms1, 2, the United States Food and Drug 
Administration (FDA) has issued a number of safety communications regarding the problem.4 
Furthermore, there have been multiple studies that have compared the effectiveness of 
duodenoscope reprocessing and/or suggested improvements to the process.4-9 
 
In August 2015, the FDA distributed a safety communication enumerating supplemental 
measures to enhance duodenoscope reprocessing.1  These 4 supplemental measures included: 
(1) microbiological culturing of duodenoscopes, (2) reprocessing with repeat high-level 
disinfection, (3) reprocessing with liquid chemical sterilization and/or (4) reprocessing with 
ethylene oxide (EtO) sterilization.1  
 
Liquid chemical sterilization (LCS) has been proposed as an alternative to standard heat or 
gas/vapor/plasma sterilization for temperature sensitive medical devices such as 
duodenoscopes.  Although unknown, there are suggestions that LCS may lead to less wear on 
endoscopes than standard sterilization procedures (ie, EtO sterilization).  Presently, there are 
no prospective studies comparing LCS with double high-level disinfection (DHLD) for 
duodenoscope reprocessing.  
 
The aim of this study is to compare the efficacy of reprocessing duodenoscopes used for ERCP 
by DHLD versus LCS by evaluating surveillance cultures obtained from duodenoscopes after 
reprocessing. We hypothesized that there would be significantly fewer positive postreprocessing 




This study is a single-center prospective, randomized study evaluating reprocessing of 
duodenoscopes with either DHLD (Cantel DSD EDGE Dual Basin AER System) or LCS (Steris 
1E system). The study time period was October 23, 2017 to September 24, 2018.  The study 
was deemed exempt from IRB review by the Indiana University School of Medicine institutional 
review board (Study no. 1901874607) because it was considered a quality/process 
improvement study that did not directly impact patient care. All routinely used duodenoscopes 
were prospectively, randomly allocated to a reprocessing strategy (DHLD or LCS) before the 
initiation of the study, and then subsequently relegated to that same reprocessing strategy for 
the duration of the entire study period.  Patients, physicians and procedural nurses were all 
blinded to the reprocessing strategy. The personnel involved with endoscope cleaning and the 
culturing process were by design not blinded to the reprocessing strategy, but were not involved 
in assessing study outcomes. 
 
In the DHLD group, duodenoscopes underwent precleaning at the bedside, then were moved to 
the decontamination area where manual cleaning was performed followed by the automated 
HLD reprocessing. The Cantel system used Rapicide OPA high-level disinfectant solution. This 
sequence of manual cleaning followed by automated HLD was then repeated for a second 
reprocessing phase.  In the LCS group, duodenoscopes underwent precleaning at the bedside, 
then were moved to the decontamination area where manual cleaning was performed followed 
by a single liquid chemical sterilization cycle. The Steris system used S40 sterilant concentrate.   
 
This study was performed at a high-volume referral center for pancreatobiliary disease (IU 
Health, University Hospital, Indianapolis, Ind, USA). From 2014 to 2018, the ERCP volume at 
this center has ranged from 2,700 to 2,900 ERCP procedures per year. All duodenoscopes 
used are manufactured by Olympus (Olympus America, Center Valley, Pa, USA). Per usual 
clinical care, the endoscopist specifies the model of duodenoscope to be used for each patient.  
The selection of the individual duodenoscope within that model line is performed by the 
endoscopy nurse from available duodenoscopes within the endoscope cabinet.  The endoscopy 
nurses for this study were blinded to the reprocessing strategy. The older model JF-130, JF-140 
and TJF-140 duodenoscopes were not prospectively randomized to a cleaning strategy.  All JF-
130, JF-140 and TJF-140 model duodenoscopes were reprocessed with DHLD, as they are not 
used routinely and there is significantly more institutional experience cleaning these 
duodenoscopes with DHLD.  Surveillance culture data for these models were collected and are 
reported herein.  
 
Duodenoscopes were randomly cultured after reprocessing.  There was an internal goal for the 
duodenoscopes to be cultured for approximately 30% of ERCPs performed per week.  There 
was a periodic evaluation of the duodenoscope culture process and distribution of 
duodenoscopes and culturing by our infection prevention specialist, to ensure all 
duodenoscopes were subject to culturing in a relatively equitable fashion. The cultures were 
appropriated by sampling the duodenoscope tip, duodenoscope tip seams, and elevator recess 
(both with elevator up and with elevator down) by with a single sterile swab. The culturing 
method has previously been described.8 Microbiology staff identified organisms by standard 
laboratory protocol, with antibiotic susceptibilities tested and reported upon request.  
 
To ensure that the duodenoscopes were not contaminated during the culture appropriation 
process, all scopes underwent an additional single HLD cycle after the culturing protocol was 
performed.  All cultured duodenoscopes were quarantined until the culture results finalized.  
Duodenoscopes that grew low-concern or high-concern organisms were recultured and 
quarantined.  Any duodenoscope that had positive growth on the reculture was then sent for 
EtO sterilization.   
 
A high concern or potentially pathogenic organism was defined according to the Department of 
Health and Human Services Collaboration report on duodenoscope surveillance sampling and 
culturing, as “organisms that are more often associated with disease,” including gram negative 
rods, gram positive organisms, Enterococcus species and yeasts.1, 10  
 
Data analysis was performed using Excel (Microsoft Corporation, Redmond, Wash, USA) and 
SAS (SAS version 15, SAS Institute Inc, Cary, NC, USA).  Sample size of 350 samples per 
group was calculated assuming a baseline incidence of 4.8% overall culture positive rate in the 
double high-level disinfection group based on a previous study from our center8, to test for a 
reduction in baseline incidence positive culture of 75% in the liquid chemical sterilization group, 
we required 350 samples per group at a significance level of 0.05 and power of 80%.  
Descriptive data are reported as mean (standard deviation) or median (interquartile range; IQR) 
for continuous variables. Categorical variables are described using frequency (proportion). Chi-
square or Fisher exact test were used for comparisons of categorical data. The Student t-test or 
Wilcoxon rank-sum test are used for comparisons of continuous variables, as appropriate. The 
level of significance is considered to be ≤ 0.05.  
 
Results 
During the study time period, 67 total duodenoscopes were clinically used that qualified for 
random allocation of reprocessing strategy.  Of these, 48 were institutional duodenoscopes 
(owned by our institution) and 19 were “loaner” duodenoscopes from the manufacturer (loaned 
to our institution for scopes out for repair or quarantine). Additionally, 10 institutional 
duodenoscopes were not eligible for random allocation (JF-130, JF-140, TJF-140), and all 
underwent DHLD. Table 1 describes the breakdown of the individual scope models in each 
group. Data are presented both including and not including the older 130 and 140 model 
duodenoscopes. 
 
During the study time period, 878 post-reprocessing surveillance cultures were drawn from all 
duodenoscopes.  There were 453 cultures drawn from the DHLD group and 425 cultures drawn 
from the LCS group.  In total, 17 cultures returned positive for any organism (1.9% of all 
cultures). There were 8 positive cultures in the DHLD group and 9 positive cultures in the LCS 
group (1.8% vs. 2.1%, respectively, p=0.8). The organisms identified for each positive culture 
are described in Table 2. There was growth of a high concern or potentially pathogenic 
organism in 2 cultures for each group (0.4% vs. 0.5%, p=1.0).  The Klebsiella pneumoniae and 
Enterobacter cloacae organisms were tested for antibiotic susceptibility. No multidrug resistant 
organisms were detected, including no carbapenem resistant enterobacteriaceae (CRE). There 
was no known transmission of organisms from a duodenoscope to a patient during the study 
period. One duodenoscope had a repeat positive culture of a low concern organism (LCS 
group) after reprocessing.  This duodenoscope was sent for EtO sterilization and subsequent 
culture was negative.  No other duodenoscopes had more than one positive culture throughout 
the duration of the study.  
 
 
Excluding the JF-130, JF-140 and TJF-140 duodenoscope cultures, a total of 796 cultures were 
appropriated from the duodenoscopes eligible for randomized reprocessing.  Of these, 371 
cultures were in the DHLD group and 425 cultures were in the LCS group.  In total, 14 cultures 
returned positive for any organism (1.8% of all cultures). There were 5 positive cultures in the 
DHLD group and 9 positive cultures in the LCS group (1.3% vs 2.1%, respectively, p=0.6). 
There was growth of a high concern or potentially pathogenic organism in 2 cultures for each 
group (0.5% vs 0.5%, p=1.0).  A total of 82 post-reprocessing surveillance cultures were drawn 
from the JF-130, JF-140 and TJF-140 model duodenoscopes.  There was growth of 3 low-
concern organisms in these cultures (3.7%). There was no growth of high-concern organisms in 
this group. In post-hoc analysis, the rate of positive surveillance cultures in the JF-130, JF-140 
and TJF-140 group reprocessed by DHLD (3.7%) was not significantly different than the group 
of newer model duodenoscope group that was randomized to DHLD (1.3%, p = 0.16).  
 
Although the time of each reprocessing procedure was not prospectively collected, post-hoc 
observations of the reprocessing team show that the approximate time of the DHLD 
reprocessing is 98 minutes (manual cleaning time 20 minutes, twice; single high-level 
disinfection cycle time 24 minutes, twice; drying time 10 minutes). The approximate time of the 
LCS reprocessing is 55 minutes (manual cleaning time 20 minutes; Single LCS cycle 25 
minutes; drying time 10 minutes).  
 
Discussion 
ERCP is an important, invasive endoscopic procedure that can have significant, life-saving 
therapeutic consequences for the patient.  The documented transmission of pathogenic 
organisms that subsequently caused harm in multiple patients in multiple centers around the 
globe revealed an infection control issue, likely related to the reusable duodenoscope design 
and also human and procedural factors related to reprocessing.  Since the initial outbreaks have 
been reported, additional measures to improve duodenoscope reprocessing have been 
recommended by the FDA, in an effort to improve the reprocessing method.1 In the past 5 
years, our center has devoted significant time and resources to improve our reprocessing 
strategy.  Some of the efforts before this current study have previously been reported.8 Despite 
recommendations for enhanced duodenoscope reprocessing by the FDA, there had been no 
prospective evaluation comparing the effectiveness of DHLD to LCS, which was the impetus of 
this study. Three of the 4 supplemental measures recommended by the FDA were incorporated 
into this current study, to attempt to determine whether one heightened reprocessing method 
(DHLD) was favorable to another (LCS).  
 
In this prospective study in which the reprocessing strategy for duodenoscopes was 
randomized, we found that DHLD and LCS both resulted in a low rate of positive surveillance 
duodenoscope cultures. Additionally, there was a very low rate of high concern or potentially 
pathogenic organism growth. There was no difference in the rate of growth of surveillance 
cultures between the 2 reprocessing strategies.  This study did not randomize the older models 
of duodenoscopes (130 and 140 series Olympus duodenoscopes). When the postreprocessing 
cultures of these duodenoscopes (all done with DHLD) were compared with the newer model 
scopes reprocessed with DHLD, there was a trend toward higher numbers of low concern 
organism growth, but no significant difference.  
 
This study had an overall rate of positive culture that was lower than the overall rate of positive 
culture (4.9%) in the final phase of our prior published study on double high-level disinfection.8 
Nonetheless, during the final phase of that study, the percentage of high-risk positive cultures 
was consistent with this current study (0.3% in prior study on DHLD and 0.5% in current study in 
DHLD arm).8 This comparative reduction in the growth of low risk organisms in the current study 
compared with the historic study may be secondary to improved training and technical 
performance of the scope cleaning team over time. Effective and continued training and 
evaluation of scope cleaning technicians and scope cleaning processes are essential to bringing 
the risk of transmission of pathogens by reusable duodenoscopes as low as possible.  
 
The strengths of this study include the prospective, randomized nature comparing 2 enhanced 
duodenoscope reprocessing strategies.  Some limitations include the following:  not all 
duodenoscopes used throughout the study period were cultured; this was performed at a high-
volume ERCP center with dedicated duodenoscope cleaning technicians, which may not be 
generalizable to all practices; and the possibility that the study was not powered to detect subtle 
differences in the reprocessing techniques.  However, it is unlikely that a higher power to detect 
a subtle overall difference would lead to a clinically relevant result. Furthermore, we did not 
include a reprocessing strategy arm of single high-level disinfection. This would have required a 
much higher enrollment goal for 3-way statistical comparisons, and the FDA at the time of the 
study had recommended supplemental measures to enhance reprocessing. Thus, a single high-
level disinfection group during the time of the study could be considered to have received 
substandard reprocessing.  
 
Duodenoscope reprocessing costs are an important consideration, particularly in the setting of 
single use duodenoscopes now being available in the market.  These costs were not 
prospectively evaluated in this study. Reprocessing strategies (including both LCS and DHLD) 
do include capital costs (the physical reprocessor), recurrent costs (the sterilant or reprocessing 
fluid, test strips, etc), training costs and labor costs (reprocessing technicians). Institutions may 
have variable costs due to volume and negotiated contracts.  At our institution, there was not a 
dramatic difference in the cost between reprocessing strategies—the capital costs and the per 
endoscope cost for reprocessing materials were similar.  
 
Despite the low rates of positive cultures, neither reprocessing strategy entirely eliminated the 
growth of high concern organisms. In a safety communication released August 2019, the FDA 
recommended that health care providers begin a transition to duodenoscopes with innovative 
designs that facilitate or eliminate the need for reprocessing.3 The current issue with infection 
control has spurred a significant amount of development into disposable components and 
single-use endoscopes, many of which are reaching the marketplace now.11-14  Nevertheless, 
these new devices have many variables including price, availability and performance that are 
unknown.  New developments in reusable scope reprocessing and sterilization are warranted. 
Optimally reprocessing reusable duodenoscopes will likely continue to be a necessity and 
priority for the foreseeable future.  Based on our study, we do not endorse any comparative 
advantage of either (DHLD or LCS) enhanced reprocessing strategy over the other.  
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Table 1: Distribution of duodenoscopes, by model, between reprocessing strategies 
 
Duodenoscope Model DHLD (n=44)* LCS (n=33)** 
TJF-Q180 7 11 
TJF-160 27 22 
JF-140 6  
JF-130 3  
TJF-140 1  
DHLD, Double high-level disinfection, LCS, liquid chemical sterilization 
*35 institutional duodenoscopes, 9 “loaner” duodenoscopes. The JF-140, JF-130 and TJF-140 
duodenoscopes were not randomly allocated – all received DHLD. 
**23 institutional duodenoscope, 10 “loaner” duodenoscopes 
 
Table 2: Organisms detected in positive cultures from all duodenoscope reprocessing 
surveillance cultures 
spp, Species 
BOLD organisms are considered high-concern organisms. 
*One culture in the DHLD group had more than one organism grow in a positive culture.  
**Three cultures in the LCS group had more than one organism grow in a positive culture.  
 
Organism DHLD (n=8 positive 
cultures)* 





Micrococcus spp.  2 
Bacillus spp. 2 3 
Streptococcus viridans  1 
Enterococcus spp.  1 
Klebsiella pneumoniae 1  
Enterobacter cloacae 1  
Acronyms and Abbreviations:  
ERCP – endoscopic retrograde cholangiopancreatography 
FDA – Food and Drug Administration 
EtO - Ethylene oxide 
DHLD - Double high-level disinfection  
LCS - Liquid chemical sterilization 
CRE - carbapenem resistant enterobacteriaceae 
Spp - species 
 
